Substrate recognition strategy for botulinum neurotoxin serotype A

被引:0
|
作者
Mark A. Breidenbach
Axel T. Brunger
机构
[1] Stanford University,Department of Molecular and Cellular Physiology
[2] Stanford University,Howard Hughes Medical Institute and Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences and Stanford Synchrotron Radiation Laboratory
来源
Nature | 2004年 / 432卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Clostridal neurotoxins (CNTs) are the causative agents of the neuroparalytic diseases botulism and tetanus1,2. CNTs impair neuronal exocytosis through specific proteolysis of essential proteins called SNAREs3. SNARE assembly into a low-energy ternary complex is believed to catalyse membrane fusion, precipitating neurotransmitter release; this process is attenuated in response to SNARE proteolysis4,5,6,7. Site-specific SNARE hydrolysis is catalysed by the CNT light chains, a unique group of zinc-dependent endopeptidases3. The means by which a CNT properly identifies and cleaves its target SNARE has been a subject of much speculation; it is thought to use one or more regions of enzyme–substrate interaction remote from the active site (exosites)8,9,10. Here we report the first structure of a CNT endopeptidase in complex with its target SNARE at a resolution of 2.1 Å: botulinum neurotoxin serotype A (BoNT/A) protease bound to human SNAP-25. The structure, together with enzyme kinetic data, reveals an array of exosites that determine substrate specificity. Substrate orientation is similar to that of the general zinc-dependent metalloprotease thermolysin11. We observe significant structural changes near the toxin's catalytic pocket upon substrate binding, probably serving to render the protease competent for catalysis. The novel structures of the substrate-recognition exosites could be used for designing inhibitors specific to BoNT/A.
引用
收藏
页码:925 / 929
页数:4
相关论文
共 50 条
  • [31] Proper dose, preparation, and storage of botulinum neurotoxin serotype A
    Anderson, ER
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (22) : S24 - S26
  • [32] Structural analysis of botulinum neurotoxin serotype F light chain: Implications on substrate binding and inhibitor design
    Agarwal, R
    Binz, T
    Swaminathan, S
    BIOCHEMISTRY, 2005, 44 (35) : 11758 - 11765
  • [33] Botulinum neurotoxin serotype C: A novel effective botulinum toxin therapy in human
    Eleopra, R
    Tugnoli, V
    Rossetto, O
    Montecucco, C
    DeGrandis, D
    NEUROSCIENCE LETTERS, 1997, 224 (02) : 91 - 94
  • [34] Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors
    Li, Bing
    Cardinale, Steven C.
    Butler, Michelle M.
    Pai, Ramdas
    Nuss, Jonathan E.
    Peet, Norton P.
    Bavari, Sina
    Bowlin, Terry L.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (24) : 7338 - 7348
  • [35] A quantitative bifunctional in vitro potency assay for botulinum neurotoxin serotype A
    Gregory, Richard W.
    Werner, William E.
    Ruegg, Curtis
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2014, 69 (02) : 103 - 107
  • [36] Recombinant botulinum neurotoxin serotype A1 in vivo characterization
    Perier, Cindy
    Martin, Vincent
    Cornet, Sylvie
    Favre-Guilmard, Christine
    Rocher, Marie-Noelle
    Bindler, Julien
    Wagner, Stephanie
    Andriambeloson, Emile
    Rudkin, Brian
    Marty, Rudy
    Vignaud, Alban
    Beard, Matthew
    Lezmi, Stephane
    Kalinichev, Mikhail
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (05):
  • [37] Solubility of the catalytic domains of Botulinum neurotoxin serotype E subtypes
    Chen, Sheng
    Barbieri, Joseph T.
    PROTEIN EXPRESSION AND PURIFICATION, 2016, 118 : 18 - 24
  • [38] Identification, synthesis, and evaluation of novel botulinum neurotoxin serotype A inhibitors
    Raghunandan, Krupanandan
    Teng, Yu-Han
    Berger, William
    Nesbitt, Natasha
    Kumar, Kunal
    Balius, Trent
    Rizzo, Robert
    Tonge, Peter
    Ojima, Iwao
    Swaminathan, Subramanyam
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [39] Structural basis for the inhibition of botulinum neurotoxin serotype A by potent peptidomimetics
    Zuniga, J.
    Hammill, J.
    Drory, O.
    Nuss, J.
    Burnett, J.
    Gussio, R.
    Wipf, P.
    Bavari, S.
    Brunger, A. T.
    TOXICON, 2013, 68 : 103 - 104
  • [40] Fungal bis-Naphthopyrones as Inhibitors of Botulinum Neurotoxin Serotype A
    Cardellina, John H., II
    Roxas-Duncan, Virginia I.
    Montgomery, Vicki
    Eccard, Vanessa
    Campbell, Yvette
    Hu, Xin
    Khavrutskii, Ilja
    Tawa, Gregory J.
    Wallqvist, Anders
    Gloer, James B.
    Phatak, Nisarga L.
    Hoeller, Ulrich
    Soman, Ashish G.
    Joshi, Biren K.
    Hein, Sara M.
    Wicklow, Donald T.
    Smith, Leonard A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (05): : 387 - 391